Blocking Inflammation Protein Extends Lifespan July 19, 2024, 7:41 p.m.
Researchers discovered that inhibiting the protein IL-11 extends the lifespan of mice by up to 25%. The treatment also reduces cancer and diseases related to aging. This breakthrough offers potential for future anti-aging therapies in humans. Further clinical trials are necessary to confirm its safety and effectiveness.
New Technique Shows Promise in Fighting Brain Cancer July 19, 2024, 7:40 p.m.
Researchers developed a new method, burst sine wave electroporation (B-SWE), to treat glioblastoma, a fast-growing brain tumor. B-SWE disrupts the blood-brain barrier more effectively than traditional methods, allowing cancer drugs better access to the brain. This technique could enhance treatment by minimizing damage to healthy brain tissue while targeting cancer cells. The study highlights a promising advance in brain cancer therapy.
Un virus courant est à l'origine d'un grave cancer du cerveau, le glioblastome July 15, 2024, 1:04 p.m.
L’infection se fait durant la prime enfance par des gouttelettes de salive et ne présente le plus souvent aucun symptôme. "Comme les autres herpès virus, le CMV s’installe à vie dans l’organisme et se réactive par poussées occasionnelles", ajoute le chercheur. Cette découverte offre des pistes de traitement contre ce cancer du cerveau actuellement incurable. "Des essais cliniques sont déjà en cours pour voir si l’utilisation d’un antiviral, le ganciclovir, pourrait ralentir la progression de la maladie mais il n’est pas sûr que le virus soit nécessaire à la progression du cancer par la suite". Une solution à plus long terme serait un vaccin contre le CMV. "Il n’existe pas encore mais nous y travaillons". Un tel vaccin chez le jeune enfant permettrait, comme dans le cas du papillomavirus et des cancers du col de l’utérus et oropharyngé, d’éviter un cancer redoutable des décennies plus tard.
Cytomegalovirus Shown to Cause Glioblastoma July 15, 2024, 12:30 p.m.
Human cytomegalovirus (hCMV) is part of the Herpesviridae family. It infects nearly half of the French population. Once infected, individuals are generally lifelong carriers of the virus, as is the case with all herpesviruses. The infection is often clinically asymptomatic. Viral transmission occurs through direct contact with the secretions of an infected person (eg, saliva, tears, urine, and feces). The virus can reactivate through occasional flare-ups.
Current Approaches to Craniopharyngioma Management July 10, 2024, 3:53 p.m.
Craniopharyngiomas (CP) are rare noncancerous brain tumors located in the skull base. To date, CP remain challenging-to-resect tumors, owing to their difficult location and invasive potential, with profound adverse effects for the patient if left to grow. Indeed, gross total resection may also be accompanied by unwelcome sequalae, underscoring the need for continued investigation. In the present work, we provide a scoping review of current CP management, with emphasis on our knowledge of their genesis, available treatment options, post-intervention clinical outcomes.
Global pediatric craniopharyngioma management modalities and outcomes July 5, 2024, 3:05 p.m.
Pediatric craniopharyngioma presents and is managed similarly across the globe. However, no studies originating from LICs and resource-poor regions examine presentation and management to date, representing a significant knowledge gap that must be addressed to complete the global picture of pediatric craniopharyngioma burden and management.
An update on multimodal management of craniopharyngioma in children July 5, 2024, 3:02 p.m.
Treatment algorithms experienced several changes over the last decades and will be subject to constant optimization. Implementation of experienced interdisciplinary networks generating individual therapeutic strategies is mandatory to avoid or minimize long-term consequences for the patient. Alternative treatments, including intracystic ORI combined with other therapies or even molecular genetic approaches may evolve further and offer more robust opportunities for function preservation in CP patients.
The Price of Success—The Long-Term Outcomes of Children with Craniopharyngioma July 5, 2024, 3:02 p.m.
The treatment outcome of children with craniopharyngioma is good, and surgery combined with radiotherapy provides comparable results to gross tumor resection in terms of progression-free survival in the majority of patients. The rate of endocrinopathies in craniopharyngioma survivors is high. Adjuvant irradiation, applied in primary or recurrence treatment, improves disease control. Children who have been treated for craniopharyngioma require close follow-up with radiological and endocrinological assessment.
Current Approaches to Craniopharyngioma Management July 5, 2024, 2:57 p.m.
The available literature on surgical invention for CP suggests that endoscopic endonasal (or transsphenoidal) approaches may provide enhanced visualization and positioning for bimanual resection of challenging tumors, resulting in favorable clinical prognoses compared to conventional transcranial interventions. Brachytherapy and intracystic therapy have enjoyed some attention as alternative, but combined surgery and conventional external beam radiation therapy remain king for most all CP at the time of writing.
Changing Care for Craniopharyngioma July 5, 2024, 2:55 p.m.
People with a rare but devastating type of brain tumor called a papillary craniopharyngioma may soon have an effective new option for treatment, according to results from a small clinical trial.
National UK guidelines for the management of paediatric craniopharyngioma July 2, 2024, 7:32 a.m.
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic–pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour itself can cause pronounced long-term neuroendocrine morbidity against a background of high overall survival. To date, the optimal management strategy for these tumours remains undefined, with practice varying between centres. In light of these discrepancies, as part of a national endeavour to create evidence-based and consensus-based guidance for the management of rare paediatric endocrine tumours in the UK, we aimed to develop guidelines, which are presented in this Review.
Craniopharyngioma July 2, 2024, 3:47 a.m.
Treatment comprises neurosurgery and radiotherapy; intracystic chemotherapy is used in monocystic ACP. Although long-term survival is high, quality of life and neuropsychological function are frequently impaired due to the close anatomical proximity to the optic chiasm, hypothalamus and pituitary gland. Indeed, hypothalamic involvement and treatment-related hypothalamic lesions frequently result in hypothalamic obesity, physical fatigue and psychosocial deficits. Given the rarity of these tumours, efforts to optimize infrastructure and international collaboration should be research priorities.
Craniopharyngioma in Childhood July 2, 2024, 3:45 a.m.
Craniopharyngiomas are unique tumors of the suprasellar region with an embryologic origin. They are the third most common cause of all intracranial tumors in childhood and the most common form involving the pituitary gland. Craniopharyngiomas have a bimodal peak of incidence, with the first peak in childhood accounting for approximately 10% of pediatric intracranial tumors. Although typically benign histologically, the suprasellar location and the size of these tumors have historically led to high rates of mortality. With modern developments in surgical technique, improvements in imaging modalities, and evolution of pre- and postoperative treatment, the immediate and long-term therapeutic options for children who have craniopharyngiomas have greatly expanded. Significant morbidity, however, is still often associated with treatment of craniopharyngiomas, and much remains to be learned about optimization of care for children who have these tumors.
Multidisciplinary Management of Craniopharyngiomas in Children: A Single Center Experience July 2, 2024, 3:41 a.m.
Our experience advises that risk-adapted surgical strategies at diagnosis should aim for a maximal degree of resection, respecting the integrity of optical and hypothalamic structures to prevent severe sequelae and therein minimize consequences that could negatively impact the patient’s QoL. STR followed by PBT results in excellent disease control for pediatric CP, with a low risk of acute toxicity. Notably, PBT does not seem to worsen pre-existing complications, namely vision, the neurocognitive domain, and endocrine function, resulting in a safe and effective option for CP management. Our preliminary experiences with PBT applied to operated CP are very promising compared to conventional irradiation, especially for localized tumors adjacent to the optic nerve/chiasm, pituitary gland, or hypothalamus. Long-term follow-ups are needed to confirm this data.
Different Treatment Modalities for Craniopharyngioma July 2, 2024, 3:38 a.m.
Uncover the secrets of craniopharyngioma treatment modalities in this informative and engaging video! Join Dr. Roopesh, your trusted neuro doctor, as he delves into the diverse and cutting-edge approaches to address craniopharyngioma, a rare brain tumor.
A Rational Approach to Management of Craniopharyngioma July 2, 2024, 3:36 a.m.
Don’t miss this recording originally broadcasted live on May 16, featuring Dr. Sandeep Kunwar and Dr. Lewis Blevins. It is a Pituitary World News production in collaboration with the Raymond A. Wood Foundation.
Llega la cirugía láser con ablación termal para el glioblastoma inoperable June 24, 2024, 10:51 a.m.
El Hospital del Mar de Barcelona ha realizado, sin complicaciones, la primera intervención mínimamente invasiva de este tipo en España.
Anlotinib plus STUPP: A new hope for glioblastoma patients June 16, 2024, 3:04 p.m.
Following the completion of chemotherapy, maintenance therapy with anlotinib as a monotherapy was initiated. The study evaluated the efficacy of this combination in extending PFS and OS, showing promising results with a median PFS of 10.9 months and a median OS of 17.4 months. The 12-month PFS and OS rates were 48.5% and 81.8%, respectively, indicating that adding anlotinib might significantly improve outcomes for glioblastoma patients.
Researchers report encouraging Phase 1 data for glioblastoma treatment June 10, 2024, 7:01 a.m.
Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
El 12 de Octubre prueba el primer CAR-T europeo en glioblastoma June 10, 2024, 7 a.m.
El Hospital público Universitario 12 de Octubre desarrolla el primer CAR-T europeo contra el tumor cerebral más agresivo, el glioblastoma, en el marco de un proyecto financiado por el Instituto de Salud Carlos III, que se encuentra en la fase de ensayo con modelo animal para ver su toxicidad, antes de dar el paso al ensayo clínico en humanos.